IRIS
GALATI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 153
EU - Europa 88
AS - Asia 19
OC - Oceania 5
SA - Sud America 3
AF - Africa 1
Totale 269
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 147
GB - Regno Unito 47
IT - Italia 19
FR - Francia 7
CA - Canada 6
IN - India 6
AU - Australia 5
DE - Germania 5
FI - Finlandia 5
TR - Turchia 5
NL - Olanda 3
PE - Perù 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
CL - Cile 1
CY - Cipro 1
HK - Hong Kong 1
JP - Giappone 1
KZ - Kazakistan 1
SA - Arabia Saudita 1
SG - Singapore 1
ZA - Sudafrica 1
Totale 269
Salva come PNG Salva come JPEG
Città #
Ashburn 68
London 44
Rome 13
Seattle 13
Council Bluffs 10
West Jordan 10
Boardman 8
Washington 7
San Francisco 6
Helsinki 5
Pune 5
Toronto 5
Amsterdam 3
Paris 3
Boydton 2
Canberra 2
Lima 2
Los Angeles 2
Melbourne 2
New York 2
Warsaw 2
Central 1
Cleveland 1
Foligno 1
Frankfurt am Main 1
Gauteng 1
Hanover 1
Newark 1
Nicosia 1
Riyadh 1
Secaucus 1
Singapore 1
Stoney Creek 1
Stow 1
Sydney 1
Totale 228
Salva come PNG Salva come JPEG
Nome #
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 14
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 11
Surgical complications after resection of adrenal carcinoma 11
Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease 11
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 11
Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy 10
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 10
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease 10
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 10
Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens 9
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 8
Peripheral graft infection due to Staphylococcus aureus without abnormal findings by 99mTc-HMPAO-labeled-leukocyte scan 8
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 7
Haemorrhoidal disease in severe portal hypertension: a combined approach with transjugular intrahepatic portosystemic shunt (TIPS) and transanal haemorrhoidal dearterialization (THD) 7
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 7
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 7
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 7
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 6
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 6
A challenging alfa-fetoprotein in a cirrhotic patient 6
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 6
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 6
Lower schooling, higher hepatitis C virus prevalence in Italy: an association dependent on age 5
Hepatic complications of bariatric surgery : the reverse side of the coin 5
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 5
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 5
Assessment of liver function by the exhaled breath-print during chronic liver disease 5
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 5
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 5
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 5
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 5
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 5
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 5
Non-cirrhotic portal hypertension with large regenerative nodules: a diagnostic challenge 4
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 4
Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis 4
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 4
GAS EXCHANGE AND PULMONARY MICROCIRCULATION ABNORMALITIES IN CIRRHOTIC AND NON-CIRRHOTIC CHRONIC LIVER DISEASE PATIENTS FREE FROM HEPATOPULMONARY SYNDROME 4
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 3
Platelet count may impact on lysosomal acid lipase activity determination in dried blood spot 3
Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis 3
The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients 2
Totale 274
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202278 0 0 4 0 0 2 0 0 5 0 0 67
2022/202330 6 0 1 1 0 0 9 3 0 1 9 0
2023/2024166 8 13 7 19 12 77 2 13 3 12 0 0
Totale 274